Recommendations for validation testing of home pregnancy tests (HPTs) in Europe.
Authors: Sturgeon, C., Butler, S.A., Gould, F., Johnson, S., Rowlands, S., Stenman, U.-H. and Grenache, D.G.
Journal: Clin Chem Lab Med
eISSN: 1437-4331
DOI: 10.1515/cclm-2020-1523
Abstract:Home pregnancy tests (HPTs) available in Europe include accuracy and other performance claims listed on their packaging. Due to the lack of guidance on the standardisation of such products, it is often difficult to replicate these claims when tested on a clinical sample, whether in a laboratory setting or by lay users. The In Vitro Diagnostic Regulation is a set of requirements that mandate comprehensive validation data on human pregnancy tests and other in vitro devices. It is due to replace the current European Directive (98/79/EC) and fully implemented in Europe by 2022. In June 2019, a panel of seven experts convened to discuss the validation studies required to provide the information needed to meet the new regulation for HPTs in Europe and proposed 15 recommendations for best practice. Defining best practice at all stages of validation of these important tests may ensure that tests marketed in Europe are fit for purpose, enabling lay users to be confident of the high quality of the HPT results they obtain. The panelists believe that the recommendations proposed here for the validation of HPTs may constructively contribute to improved standardisation of validation procedures in Europe.
https://eprints.bournemouth.ac.uk/35164/
Source: PubMed
Recommendations for validation testing of home pregnancy tests (HPTs) in Europe.
Authors: Sturgeon, C., Butler, S.A., Gould, F., Johnson, S., Rowlands, S., Stenman, U.-H. and Grenache, D.G.
Journal: Clinical chemistry and laboratory medicine
eISSN: 1437-4331
ISSN: 1434-6621
DOI: 10.1515/cclm-2020-1523
Abstract:Home pregnancy tests (HPTs) available in Europe include accuracy and other performance claims listed on their packaging. Due to the lack of guidance on the standardisation of such products, it is often difficult to replicate these claims when tested on a clinical sample, whether in a laboratory setting or by lay users. The In Vitro Diagnostic Regulation is a set of requirements that mandate comprehensive validation data on human pregnancy tests and other in vitro devices. It is due to replace the current European Directive (98/79/EC) and fully implemented in Europe by 2022. In June 2019, a panel of seven experts convened to discuss the validation studies required to provide the information needed to meet the new regulation for HPTs in Europe and proposed 15 recommendations for best practice. Defining best practice at all stages of validation of these important tests may ensure that tests marketed in Europe are fit for purpose, enabling lay users to be confident of the high quality of the HPT results they obtain. The panelists believe that the recommendations proposed here for the validation of HPTs may constructively contribute to improved standardisation of validation procedures in Europe.
https://eprints.bournemouth.ac.uk/35164/
Source: Europe PubMed Central
Recommendations for validation testing of home pregnancy tests (HPTs) in Europe.
Authors: Sturgeon, C., Butler, S.A., Gould, F., Johnson, S., Rowlands, S., Stenman, U.-H. and Grenache, D.G.
Journal: Clinical Chemistry and Laboratory Medicine
Volume: 59
Issue: 5
Pages: 823-835
ISSN: 1437-4331
Abstract:Home pregnancy tests (HPTs) available in Europe include accuracy and other performance claims listed on their packaging. Due to the lack of guidance on the standardisation of such products, it is often difficult to replicate these claims when tested on a clinical sample, whether in a laboratory setting or by lay users. The In Vitro Diagnostic Regulation is a set of requirements that mandate comprehensive validation data on human pregnancy tests and other in vitro devices. It is due to replace the current European Directive (98/79/EC) and fully implemented in Europe by 2022. In June 2019, a panel of seven experts convened to discuss the validation studies required to provide the information needed to meet the new regulation for HPTs in Europe and proposed 15 recommendations for best practice. Defining best practice at all stages of validation of these important tests may ensure that tests marketed in Europe are fit for purpose, enabling lay users to be confident of the high quality of the HPT results they obtain. The panelists believe that the recommendations proposed here for the validation of HPTs may constructively contribute to improved standardisation of validation procedures in Europe.
https://eprints.bournemouth.ac.uk/35164/
Source: BURO EPrints